Wells Fargo analyst Brandon Couillard initiated coverage of Bio-Techne (TECH) with an Overweight rating and $59 price target The firm believes Bio-Techne’s “unique” portfolio is well positioned to deliver sustained above-average organic revenue and earnings growth. The company is exposed to high-growth verticals, such as good manufacturing practice reagents, proteomic instruments, spatial biology and precision diagnostics, the analyst tells investors in a research note. Wells believes the recent pullback in the shares offers a compelling entry point.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: